Unexpected Peaks in Chromatograms - Are They Related Compounds, System Peaks or Contaminations? From the Diary of an HPLC Detective

Similar documents
High Performance Liquid Chromatography

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

Agilent 1200 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

Transferring HPLC methods from the HP 1090 Series to the Agilent 1100 Series HPLC system

High Pressure/Performance Liquid Chromatography (HPLC)

High Performance Liquid Chromatography

High Performance Liquid Chromatography

ANALYTICAL METHOD DETERMINATION OF VOLATILE ALDEHYDES IN AMBIENT AIR Page 1 of 11 Air sampling and analysis

The Theory of HPLC. Quantitative and Qualitative HPLC

Basic principles of HPLC

FAQ's. 1 - Which column would be the most appropriate for my application?

Assay Transfer from HPLC to UPLC for Higher Analysis Throughput

Chromatography. Gas Chromatography

Mobile-Phase Cleanup Using Solid-Phase Extraction Disks

Principles of Gas- Chromatography (GC)

ISSN Review Article A Review: HPLC Method Development and Validation

Chromatographic Analysis

LC800. Smart HPLC. Until now UHPLC From now Smart HPLC


Chromatography Outline

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

Luminescence transitions. Fluorescence spectroscopy

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

Chapter content. Reference

Prep 150 LC System: Considerations for Analytical to Preparative Scaling

Barry E. Boyes, Ph.D. Consumables and Accessories Business Unit May 10, 2000

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

Tips & Tricks GPC/SEC: Quantify and Get More Than Molar Mass Averages

for Acclaim Mixed-Mode HILIC-1 Column

Determination of Polyacrylic Acid in Boiler Water Using Size-Exclusion Chromatography with Charged Aerosol Detection

LC III: HPLC. Originally referred to as High-Pressure Liquid Chromatography. Now more commonly called High Performance Liquid Chromatography

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

MODERN HPLC FOR PRACTICING SCIENTISTS

SCPC Systems for Liquid-Liquid Extraction

HPLC. High Performance Liquid Chromatography (HPLC) Harris Chapter 25

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

M > ACN > > THF

Comparison of different aqueous mobile phase HPLC techniques

Determination of Caffeine by HPLC

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Achieve confident synthesis control with the Thermo Scientific ISQ EC single quadrupole mass spectrometer

Analysis of Positional Isomers of Lapatinib with Agilent Poroshell 120 PFP Columns

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Determination of underivatized aflatoxins B2, B1, G2, and G1 in ground hazelnuts by immunoaffinity solid-phase extraction with HPLC-FLD detection

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

Volume 6, Issue 2, January February 2011; Article-015

LC and LC/MS Column Selection Flow Chart

HPLC analysis of VFAs, Furfural and HMF

Liquid storage: Holds the solvent which is going to act as the mobile phase. Pump: Pushes the solvent through to the column at high pressure.

Validation of an Analytical Method

Application Note. Author. Abstract. Xinlei Yang Agilent Technologies Co. Ltd Shanghai, China

Chem 230, Fall, 2014 Homework Set # 3 Short Answer SOLUTIONS

The Secrets of Rapid HPLC Method Development. Choosing Columns for Rapid Method Development and Short Analysis Times

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

Potential sources of contamination on Mass Spectrometers and suggested cleaning procedures

Peptide Isolation Using the Prep 150 LC System

Quantification of Furocoumarins

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Open Column Chromatography, GC, TLC, and HPLC

Dilution(*) Chromatography

LC Column Troubleshooting. Do you have an equivalent column for my LC column?

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

High-Resolution Sampling 2D-LC for Pharmaceutical Impurity Analysis

Technical Procedure for Concentration Determination of Methamphetamine in Liquids via HPLC

HPLC Separation Fundamentals. Ed Kim Application Engineer Agilent Technologies, Inc January 14, 2009

Chromatography- Separation of mixtures CHEM 212. What is solvent extraction and what is it commonly used for?

for Acclaim Mixed-Mode WCX-1

HPLC Background Chem 250 F 2008 Page 1 of 24

Analysis of DNPH-derivatized Aldehydes and Ketones using the Agilent 1220 Infinity LC System with Diode Array Detector

High Performance Liquid Chromatography

Chromatography & instrumentation in Organic Chemistry

Automating Method Development with an HPLC System Optimized for Scouting of Columns and Eluents

HPLC Praktikum Skript

Value of Eclipse Plus C18 and ph Selectivity to Analyze Amine-Containing Drugs

High Performance Liquid Chromatography (HPLC) of Three Analgesics

Chemistry Gas Chromatography: Separation of Volatile Organics

Introduction to Pharmaceutical Chemical Analysis

Agilent LC & LC-MS Cannabis Testing

[ CARE AND USE MANUAL ]

Quantitative Analysis of Caffeine in Energy Drinks by High Performance Liquid Chromatography

Peptide and protein analysis by capillary HPLC Optimization of chromatographic and instrument parameters. Application. Angelika Gratzfeld-Huesgen

Liquid Chromatography

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

Welcome to our E-Seminar: Choosing HPLC Columns for Faster Analysis Smaller and Faster

Chromatography and other Separation Methods

HPLC. GRATE Chromatography Lab Course. Dr. Johannes Ranke. September 2003

International Journal of Current Trends in Pharmaceutical Research. International Journal of Current Trends in Pharmaceutical Research

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form

Validated HPLC Methods

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Validation Aspect In Multicomponent Fraction From Gokshur (Tribulus terrestris Linn.) By RP- HPLC Method

Automated method development using Agilent 1100 Series HPLC systems, Agilent ChemStation and ChromSword software. Application

LECTURE 2. Advanced Separation Science Techniques Present and Future Separation Tools

Packings for HPLC. Packings for HPLC

GUIDELINES FOR THE DESIGN OF CHROMATOGRAPHIC ANALYTICAL METHODS INTENDED FOR CIPAC COLLABORATIVE STUDY

Transcription:

Unexpected Peaks in Chromatograms - Are They Related Compounds, System Peaks or Contaminations? From the Diary of an HPLC Detective SHULAMIT LEVIN

HPLC in Pharmaceutics Σ

Stability Indicating Methods Extra Sensitive to Extraneous Peaks Accurately quantifies the active pharmaceutical ingredient without interference from: Impurities Degradation products Excipients Other potential impurities Other active ingredients FDA Guidelines: Where an analytical method reveals the presence of impurities in addition to the degradation products (e.g., impurities arising from the synthesis of the drug substance), the origin of these impurities should be discussed.

Accounting for Every Peak in the Related Compounds Profile - Even Down to 0.003 %Area Compound Retention Time () Area % Signal-to- Noise Impurity 1 2.174 0.0054 4.1 Impurity 2 2.231 0.0229 16.4 Butamben 2.263 99.954 64544 Butamben Impurity 3 Impurity 4 2.504 2.549 0.0037 0.0106 2.6 5.8 Impurity 5 2.714 0.0034 2.2 >LOQ

50.00 Sample vs. Blank (Diluent) Unexpected peaks can appear in blanks and in all following injections In this case they are excluded from the processing of the sample 40.00 30.00 Blank mau 20.00 10.00????? 0.00 50.00 40.00 30.00 Sample mau 20.00 10.00 0.00 0.00 10.00 20.00 30.00 40.00 50.00

INJECTION OF PURE SOLVENT: Why would there be peaks? Injection System Peak??? Carry over??? Contamination???

System Peaks Legitmate System Peaks Originate from the Mobile Phase Components Going Through Re-Equilibration

CONDITIONS FOR APPEARANCE OF REAL SYSTEM PEAKS Mobile phase is multi-component (n=>2) Mobile phase contains adsorbable components Mobile phase s components respond to the detector (high background) Sample or sample-diluent is different from the mobile phase, enough to create equilibrium perturbation.

Vacancy Mechanism of of System Peaks Formation EXAMPLE: Two additives in the mobile phase k' = t R - t 0 t 0 k = C f s Cm Example: k (1) k = 1 Step 1: Equilibrium: Cs=1; Cm = 1 Step 2: Injection of Vacancy: Cs=1; ; Cm=0 Step 3: Re-equilibration: equilibration: Cs=0.5; Cm=0.5 Example: k (2) k = 2 Step 1: Equilibrium: Cs=2; Cm = 1 Step 2: Injection of Vacancy: Cs=2; ; Cm=0 Step 3: Re-equilibration: equilibration: Cs=1.33; Cm=0.67 CHROMATOGRAM t 0 k =1 k =2

Injection of free amino acids into mobile phase containing: Ac buffer, CuAc,, and Heptsulfonate. Diluent: Water Levin and Grushka Dr. Shulamit Levin 2005, Medtechnica

Legitimate System Peaks Result from Mobile phase components due to their absence in the injected sample Levin and Abu-Lafi Injection of Blank = Water Conclusion: Use mobile phase composition as the diluent Dr. Shulamit Levin 2005, Medtechnica

An Example for Real System Peaks in Gradients with Trifluoroacetic Acid (TFA) in the Mobile Phase Peptide Peak Sample=Peptide Dissolved in Water Blank = Mobile phase TFA Blank = Mobile phase Zoomed ACN Blank =Water System peaks appear because diluent does not contain TFA

Real System Peaks in Multi-component Mobile Phase H 2 O, MeCN, MeOH, THF Chromatogram and Peaks' UV-VIS Spectra 220.00 Cpd 2-2.364 nm 220.00 240.00 260.00 280.00 300.00 320.00 340.00 2.817 nm 220.00 240.00 260.00 280.00 300.00 320.00 340.00 2.981 nm 240.00 260.00 280.00 300.00 320.00 340.00 AU 0.00-0.10-0.20-0.30-0.40 Cpd 2-2.364 2.817 2.981 THF Wavelength: 215nm -0.50 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00 Diluent does not contain all mobile phase components

Contaminations Peaks - Not System Peaks! Phosphate Buffer and Acetonitril Do Not Produce Such System Peaks! 0.006 0.005 0.004 Mobile phase: ACN : Phosphate Buffer ph 9.5 1:1 Wavelength: 280 nm 0.003 3.404 AU 0.002 0.001 0.000 2.373 2.731 4.274 6.477 18.274-0.001-0.002 Sample Name: Diluent -0.003 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00

Use of Diode-Array Detector for Troubleshooting of Contamination Peaks in Multicomponent Mobile Phase Cpd 2-2.188 250.00 nm 300.00 Chromatogram and Peaks' UV-VIS Spectra 250.00 2.748 nm 300.00 250.00 2.867 nm 300.00 Aromatic (not in mobile phase) 250.00 3.180 nm 300.00 250.00 4.226 nm 300.00 Negative UV spectrum AU 0.015 0.010 0.005 0.000 Cpd 2-2.188 2.748 2.867 3.180 Wavelength: 254.0 nm 4.226 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00 5.20 5.40 5.60 5.80 6.00

Carry Over: Chemical Residues in the system Residues in the injector Non-specific irreversible adsorption on column Accumulation on system s s surfaces

Carry Over in the Injector Washed by Blank Injection A1100 VWD AU - A1100 AU 286 nm 0.0004 AU 0.0003 0.0002 0.0001 11.334 Blank Injection 1 0.0000-0.0001 A1100 VWD AU - A1100 AU 286 nm 0.0004 AU 0.0003 0.0002 0.0001 Blank Injection 2 Contamination is cleaned 0.0000-0.0001 8.00 8.50 9.00 9.50 10.00 10.50 11.00 11.50 12.00 12.50 13.00 13.50 14.00 14.50

Blank Injections Signals are reduced from Injection to Injection indicate carry over in the injector 100.00 Series of Blank Injections 80.00 60.00 mau 40.00 20.00 0.00 0.00 10.00 20.00 30.00 40.00 50.00

Carry-Over in the Injector LC-MS/MS 1. Peak elutes at RT of main component 2. MRM of the main component Blank Sample after wash Blank Sample before wash Injection-Clean Clean-up with EDTA solved the problem

Carry Over: Residues in the system Residues in the injector Non-specific irreversible adsorption on column Accumulation on system s s surfaces

Accumulation on Column AU 0.0010 0.0005 MAIN1 Sample 0.0000 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 SampleName: SST; Vial: 1; Injection: 1; Name: MAIN1; Area: 833913 0.0010 AU 0.0005 0.0000 MAIN1 Blank #1 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 SampleName: DILUENT; Vial: 2; Injection: 1; Name: MAIN1; Area: 5063 AU 0.0010 0.0005 Cleaned Not Cleaned MAIN1 Blank #2 0.0000 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 SampleName: DILUENT; Vial: 2; Injection: 2; Name: MAIN1; Area: 4784

Contamination Peaks TFA Containing Mobile Phase: TFA, H 2 O, MeCN - Do Not Contain Aromatic Components! Chromatogram and UV-VIS Spectra of Contamination Peaks nm AU 340.00 320.00 300.00 280.00 260.00 240.00 220.00 200.00 0.002 0.001 0.000 8.510 11.604 41.142 Aromatic group Aromatic group 8.510 11.604 41.142-0.001-0.002 Diluent at 280 nm 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00

Peaks of aromatic compounds in non aromatic mobile phase: Cannot be Legitimate System Peaks Chromatogram and UV -VIS Spectra - of a Blank Run 1.066 1.553 2.362 3.695 6.237 6.418 24.320 26.940 27.026 350.00 nm 300.00 250.00 0.20 1.066 1.553 2.362 3.695 6.418 6.237 24.320 26.940 27.026 AU 0.00-0.20 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 Sample Name: blank ; Wavelength: 214 Mobile phase: Gradient of 0.1% TFA in water with ACN

Contamination Peaks - Residues Contamination on-column and/or in the mobile phase Chromatogram and UV-VIS Spectra of Contaminations Peaks nm 340.00 320.00 300.00 280.00 260.00 240.00 220.00 200.00 1.274 1.514 1.731 8.500 11.633 34.345 36.595 37.612 41.018 42.128 Aromatic compounds not legitimate components of the mobile phase AU 0.030 0.025 0.020 0.015 0.010 0.005 0.000 1.5141.274 1.731 Blank=Diluent at 220 nm 8.500 11.633 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 34.345 36.595 37.612 41.018 42.128 Gradient with TFA

Carry Over: Residues in the system Residues in the injector Non-specific irreversible adsorption on column Accumulation on system s s surfaces

Contaminations Origin Outside the Sample Non-pure solvents Vials leachables Reservoir s leachables

0.030 0.025 Baseline at Gradient Change of Baseline with Time at Various Wavelengths: Indication for non pure solvent 220 nm 100.00 80.00 AU 0.020 0.015 0.010 0.005 0.000 230 nm 254 nm 280 nm 5.00 15.00 25.00 35.00 45.00 55.00 Gradient s Profile 60.00 40.00 20.00 0.00 % Composition

-2.919PG Non-Pure/Contaminated Solvents Used in Gradients Contaminations can also come from the Parafilm used to seal reservoirs!!! -4.525-6.896 BHA -10.633BHT Sample TBHQ 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 Blank 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00

Sample vs Blank If Solvents are not entirely pure their impurities are adsorbed on the Stationary Phase at the beginning of the run and then elute from the column as the gradient develops. 50.00 40.00 30.00 This is the reason why there are Gradient Grade solvents Blank mau 20.00 10.00 0.00 50.00 40.00 30.00 Sample mau 20.00 10.00 0.00 0.00 10.00 20.00 30.00 40.00 50.00

Peak s s Origin: Contamination accumulated on pump s s in-line filter Pressure Jump Bubble-Detection Unexpected Baseline Perturbation

Contaminations Origin Outside the Sample Non-pure solvents Vials leachables Reservoir s leachables

Contamination from Vials Surfaces 0.0012 0.0010 0.0008 Non-Certified 0.0006 AU 0.0004 0.0002 0.0000-0.0002 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 0.0014 AU 0.0012 0.0010 0.0008 0.0006 Change of vial brand In the same experiment! Certified 0.0004 0.0002 0.0000-0.0002 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00

Contamination is developed during the experiment in complex Diluents (Sample s s Solvent) 0.020 0.015 AU 0.010 0.005 0.000 Contamination 0.020 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 SampleName: Sample; Vial: 1:F,1; Injection: 1; Name: Contamination 0.015 AU 0.010 0.005 0.000 Contamination 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 SampleName: Diluent ; Vial: 1:E,2; Injection: 1; Name: Contamination

Contaminations Origin Outside the Sample Non-pure solvents Vials leachables Reservoir or Column s leachables

Contamination Peaks in Size Exclusion Chromatography (SEC) Contamination is NOT a monomer! 0.030 Chromatogram at 210 nm 0.025 0.020 0.015 Sample Contamination Monomer AU 0.010 0.005 0.000-0.005 Blank Higher Molecular Weight -0.010 0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00

Other Reasons for Extraneous Peaks

Column s s Packing Collapse All Peaks are split

Suggested Flow-Chart for Troubleshooting In a Regulated Environment (no change in method!) Injection Carry over??? System Peak??? Contamination??? Yes? No Mobile phase: Multicomponent? Adsorbed components (ion pair)? Response in detector (background)? Yes? Legitimate System Peaks Dissolve samples in mobile phase Adjust diluent with mobile phase components

Suggested Flow-Chart for Troubleshooting Contd. Steps: by ease of use 1. Review and revise diluent s composition 2. Replace vials batch and/or brand 3. Replace in-line filters 4. Replace solvents batch and/or brand 5. Try a new/fresh column 6. Wash system, especially injector Make sure to try a fresh blank each test! Not washed by blanks? Not System Peaks? Peaks still persist? Replace injector s surfaces Peaks still persist? Try another instrument/operator/lab

Many times the extraneous peak disappears on its own and remains an unsolved mystery